Cell-Based Therapies in Neonatal Stroke

Tsuji, Masahiro; Johnston, Michael V.

doi:10.1007/978-3-319-15063-5_17

Cited by 2 publications

(1 citation statement)

References 113 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, propelled by the demand of patients' families and society in general, several clinical trials, including ours, that use autologous UCBC therapy to treat neonatal brain injury have already begun [42,43] (US National Institutes of Health, ClinicalTrials.gov IDs: NCT00593242, NCT01506258, NCT01649648, and NCT02256618). Nevertheless, there is still much to be explored in preclinical studies in order to determine the optimal treatment protocols and mechanisms of action of UCBC therapies.…”

Section: Discussionmentioning

confidence: 99%

Evaluations of Intravenous Administration of CD34<sup>+</sup> Human Umbilical Cord Blood Cells in a Mouse Model of Neonatal Hypoxic-Ischemic Encephalopathy

Ohshima

Taguchi²,

Sato³

et al. 2016

Dev Neurosci

Self Cite

View full text Add to dashboard Cite

Several cell therapies have been explored as novel therapeutic strategies for neonatal encephalopathy because the benefits of current treatments are limited. We previously reported that intravenous administration of human umbilical cord blood (hUCB) CD34⁺ cells (hematopoietic stem cells/endothelial progenitor cells) at 48 h after insult exerts therapeutic effects in neonatal mice with stroke, i.e., permanent middle cerebral artery occlusion. Although neonatal stroke and hypoxic-ischemic encephalopathy (HIE) are grouped under the term “neonatal encephalopathy,” their pathogenesis differs. However, little is known about the differences in the effects of the same treatment between these 2 diseases. In this study, we investigated whether the same treatment protocol exerts therapeutic effects in neonatal mice with HIE. The treatment significantly ameliorated the decreased cerebral blood flow in the ischemic penumbra. Although the cylinder and rotarod tests showed a trend of amelioration of behavioral impairments from the treatment, these were not statistically significant. Morphological brain injuries were not altered by treatment. The cell administration did not cause any adverse effects apart from hyperactivity in the open-field test. Some of these findings are consistent with the results obtained in our previous study using a stroke model, but others are not. This study suggests that the treatment protocol needs to be optimized for each pathological condition.

show abstract

Section: Discussionmentioning

confidence: 99%